170 related articles for article (PubMed ID: 37264710)
1. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X
Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710
[TBL] [Abstract][Full Text] [Related]
2. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
4. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.
Liu Y; Qiu N; Shen L; Liu Q; Zhang J; Cheng YY; Lee KH; Huang L
J Control Release; 2020 Jul; 323():431-441. PubMed ID: 32360890
[TBL] [Abstract][Full Text] [Related]
5. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy.
Li J; Zhao M; Liang W; Wu S; Wang Z; Wang D
J Control Release; 2022 Feb; 342():308-320. PubMed ID: 35031387
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
Qin T; Xu X; Zhang Z; Li J; You X; Guo H; Sun H; Liu M; Dai Z; Zhu H
Nanotechnology; 2020 Sep; 31(36):365101. PubMed ID: 32434167
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting liposomes with active recognition of GLUT
Pu Y; Zhang H; Peng Y; Fu Q; Yue Q; Zhao Y; Guo L; Wu Y
Eur J Med Chem; 2019 Dec; 183():111720. PubMed ID: 31553933
[TBL] [Abstract][Full Text] [Related]
10. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer.
Qiu X; Qu Y; Guo B; Zheng H; Meng F; Zhong Z
J Control Release; 2022 Jan; 341():498-510. PubMed ID: 34883139
[TBL] [Abstract][Full Text] [Related]
11. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
[TBL] [Abstract][Full Text] [Related]
12. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
13. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
[TBL] [Abstract][Full Text] [Related]
15. Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.
Chen M; Miao Y; Qian K; Zhou X; Guo L; Qiu Y; Wang R; Gan Y; Zhang X
Nano Lett; 2021 Jul; 21(14):6031-6041. PubMed ID: 34240603
[TBL] [Abstract][Full Text] [Related]
16. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
17. A marine-derived small molecule induces immunogenic cell death against triple-negative breast cancer through ER stress-CHOP pathway.
Wen H; Zhong Y; Yin Y; Qin K; Yang L; Li D; Yu W; Yang C; Deng Z; Hong K
Int J Biol Sci; 2022; 18(7):2898-2913. PubMed ID: 35541893
[TBL] [Abstract][Full Text] [Related]
18. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells.
Zhu Y; Wang A; Zhang S; Kim J; Xia J; Zhang F; Wang D; Wang Q; Wang J
J Adv Res; 2023 Jul; 49():159-173. PubMed ID: 36167294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
